title: Chronic seizures increase glucose transporter abundance in rat brain.
abstract: Pentylenetetrazole and kainic acid, seizure-inducing agents that are known to increase glucose utilization in brain, were used to produce chronic seizures in mature rats. To test the hypothesis that increased brain glucose utilization associated with seizures may alter glucose transporter expression, polyclonal carboxyl-terminal antisera to glucose transporters (GLUT1 and GLUT3) were employed with a quantitative immunocytochemical method and immunoblots to detect changes in the regional abundances of these proteins. GLUT3 abundances in control rats were found to be correlated with published values for regional glucose utilization in normal brain. Following treatment with kainic acid and pentylenetetrazole, both GLUT3 and GLUT1 increased in abundance in a region and isoform-specific manner. GLUT3 was maximal at eight hours, whereas GLUT1 was maximal at three days. Immunoblots indicated that most of the GLUT3 increase was accounted for by the higher molecular weight component of the GLUT3 doublet. The rapid response time for GLUT3 relative to GLUT1 may be related to the rapid increase in neuronal metabolic energy demands during seizure. These observations support the hypothesis that glucose transporters may be upregulated in brain under conditions when brain glucose metabolism is elevated.
authors.affiliation: Department of Biology, School of Medicine, University of Minnesota, Duluth 55812, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Gronlund
authors.forename: D Z
authors.initials: DZ
authors.lastname: Gerhart
authors.forename: R L
authors.initials: RL
authors.lastname: Leino
authors.forename: A L
authors.initials: AL
authors.lastname: McCall
authors.forename: L R
authors.initials: LR
authors.lastname: Drewes
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002908:Chronic Disease; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D015151:Immunoblotting; D007150:Immunohistochemistry; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D009004:Monosaccharide Transport Proteins / Q000378:metabolism*; D009419:Nerve Tissue Proteins; D010433:Pentylenetetrazole / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012640:Seizures / Q000378:metabolism*; D013997:Time Factors
chemical_list: D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D009004:Monosaccharide Transport Proteins; D009419:Nerve Tissue Proteins; C495679:Slc2a1 protein, rat; C495690:Slc2a3 protein, rat; D007608:Kainic Acid; D010433:Pentylenetetrazole